0
0
Scientists at Duke-NUS Medical School have uncovered the cause of a rare and previously undiagnosed multi-organ disorder, identifying mutations in the SPNS1 gene as the culprit. This breakthrough, detailed in the Journal of Clinical Investigation in August 2025, explains how faulty versions of SPNS1 disrupt the cellular recycling of fat molecules, leading to harmful fat and cholesterol buildup and progressive damage to the liver and muscles. The discovery also opens new avenues for personalized treatment development through collaboration with the N = 1 Collaborative, offering hope to affected children and families.
Mutations in SPNS1 Affect Cellular Recycling
The SPNS1 gene encodes a transporter protein essential for recycling lysophospholipids—a key class of fat molecules—inside lysosomes, the cell’s recycling centers. Normally, SPNS1 moves degraded fats, such as phospholipids, out of lysosomes so they can be reused for cell membrane repair or converted into energy. Mutations in both copies of SPNS1 impair this critical transport process, resulting in the accumulation of fats and cholesterol within lysosomes and causing cellular damage, particularly in the liver and muscles.
The research team studied two unrelated families whose children suffered from unexplained liver disease and muscle weakness. Genetic analysis revealed homozygous mutations in SPNS1. This foundational work built on previous studies that established SPNS1’s role in lysosomal fat recycling, adding a clear genetic and molecular cause for the disorder.
Clinical and Biological Insights
This disorder belongs to the lysosomal storage disease family, consisting of over 70 rare disorders characterized by defective cellular recycling. Patients with SPNS1 mutations present with progressive liver damage, muscle weakness, developmental delay, and neurological impairments such as intellectual disability and cerebellar hypoplasia. Mouse models lacking SPNS1 experience embryonic lethality and exhibit similar lipid accumulation and organ dysfunction, further supporting the critical role of SPNS1 in normal physiology.
Biochemically, the SPNS1 mutations disrupt the salvage pathway of lysophospholipids, affecting pathways regulated by mTOR and nutrient sensing, which are key to maintaining energy balance and healthy cell function. Accumulated lipids interfere with cell signaling, causing tissue damage that manifests as the multi-organ symptoms observed in patients.
Moving Toward Treatment
With a clearer understanding of the molecular mechanism, researchers are working with the N=1 Collaborative to develop personalized therapies targeting the disrupted fat transport pathways. These efforts include exploring novel gene and RNA therapies aimed at correcting the faulty SPNS1 function. Such targeted treatments hold promise for improving quality of life and outcomes for patients with this ultra-rare disease, for whom no established therapies currently exist.
Expert Perspectives
Ms. He Menglan, an MD-PhD student and first author, emphasized the significance of uncovering this “crucial puzzle piece” in resolving a long-standing medical mystery. Dr. Marlen Lauffer, a senior researcher and co-author, highlighted the importance of translating these scientific insights into patient-centered therapies.
Professor David Silver, Deputy Director of the Cardiovascular & Metabolic Disorders Programme at Duke-NUS, noted that while SPNS1 deficiency is extremely rare, studying it enriches understanding of lysosomal biology and lipid metabolism with broader implications. He stressed the potential of gene therapy for affected individuals and the need for sustained research to tackle translational barriers in ultra-rare conditions.
Implications for Public Health
This discovery demonstrates the power of genetic and molecular research in diagnosing previously unexplained diseases, potentially enabling earlier and more precise interventions. It highlights the necessity of genomics in rare disease research and emphasizes personalized medicine’s growing role in tailoring treatments to individual genetic profiles.
For health practitioners, awareness of this condition is critical to consider genetic testing in children with unexplained multi-organ symptoms, particularly liver disease combined with muscle weakness. For affected families, this breakthrough provides hope for targeted therapies and underscores the importance of participation in research initiatives.
Limitations and Future Directions
As SPNS1 mutations cause an ultra-rare disorder, findings are based on a small number of patients and preclinical models. Wider studies are needed to fully elucidate the disease spectrum and to optimize therapeutic strategies. Additionally, translating gene therapies from experimental to clinical use involves regulatory, safety, and accessibility challenges.
The researchers plan to deepen understanding of SPNS1’s molecular pathways and to expand collaborative efforts to bring personalized treatments to patients worldwide.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
